249 related articles for article (PubMed ID: 26265611)
1. CYP2C19*2 and Other Allelic Variants Affecting Platelet Response to Clopidogrel Tested by Thrombelastography in Patients with Acute Coronary Syndrome.
Liu J; Nie XY; Zhang Y; Lu Y; Shi LW; Wang WM
Chin Med J (Engl); 2015 Aug; 128(16):2183-8. PubMed ID: 26265611
[TBL] [Abstract][Full Text] [Related]
2. The relationship between on-clopidogrel platelet reactivity, genotype, and post-percutaneous coronary intervention outcomes in Chinese patients.
Tang N; Yin S; Sun Z; Xu X; Qin J
Scand J Clin Lab Invest; 2015 May; 75(3):223-9. PubMed ID: 25594796
[TBL] [Abstract][Full Text] [Related]
3. Effects of individualized antiplatelet therapy based on CYP2C19 genotype and platelet function on the prognosis of patients after PCI.
Zhang M; Wang JR; Zhang Y; Zhang P; Ren MY; Jia XM; Ma LP; Gao M; Hou YL
Eur Rev Med Pharmacol Sci; 2020 Oct; 24(20):10753-10768. PubMed ID: 33155236
[TBL] [Abstract][Full Text] [Related]
4. Platelet reactivity in the early and late phases of acute coronary syndromes according to cytochrome P450 2C19 phenotypes.
Nagashima Z; Tsukahara K; Morita S; Endo T; Sugano T; Hibi K; Himeno H; Fukui K; Umemura S; Kimura K
J Cardiol; 2013 Sep; 62(3):158-64. PubMed ID: 23886632
[TBL] [Abstract][Full Text] [Related]
5. CYP2C19 polymorphisms and coronary heart disease risk factors synergistically impact clopidogrel response variety after percutaneous coronary intervention.
Liu T; Yin T; Li Y; Song LQ; Yu J; Si R; Zhang YM; He Y; Guo WY; Wang HC
Coron Artery Dis; 2014 Aug; 25(5):412-20. PubMed ID: 24608794
[TBL] [Abstract][Full Text] [Related]
6. Haplotype of platelet receptor P2RY12 gene is associated with residual clopidogrel on-treatment platelet reactivity.
Nie XY; Li JL; Zhang Y; Xu Y; Yang XL; Fu Y; Liang GK; Lu Y; Liu J; Shi LW
J Zhejiang Univ Sci B; 2017 Jan.; 18(1):37-47. PubMed ID: 28070995
[TBL] [Abstract][Full Text] [Related]
7. Effects of CYP2C19 allelic variants on inhibition of platelet aggregation and major adverse cardiovascular events in Japanese patients with acute coronary syndrome: The PRASFIT-ACS study.
Ogawa H; Isshiki T; Kimura T; Yokoi H; Nanto S; Takayama M; Kitagawa K; Nishikawa M; Miyazaki S; Ikeda Y; Nakamura M; Tanaka Y; Saito S
J Cardiol; 2016 Jul; 68(1):29-36. PubMed ID: 26521100
[TBL] [Abstract][Full Text] [Related]
8. Genetic determinants of high on-treatment platelet reactivity in clopidogrel treated Chinese patients.
Zhang L; Chen Y; Jin Y; Qu F; Li J; Ma C; Yang J; Xu B; Wang H; Li X; Li Y; Zhang Y; Lu C; Yin T
Thromb Res; 2013 Jul; 132(1):81-7. PubMed ID: 23726091
[TBL] [Abstract][Full Text] [Related]
9. Interaction analysis between genetic polymorphisms and pharmacodynamic effect in patients treated with adjunctive cilostazol to dual antiplatelet therapy: results of the ACCEL-TRIPLE (Accelerated Platelet Inhibition by Triple Antiplatelet Therapy According to Gene Polymorphism) study.
Kim IS; Jeong YH; Park Y; Yoon SE; Kwon TJ; Park JR; Hwang SJ; Koh EH; Kwak CH; Hwang JY; Kim S
Br J Clin Pharmacol; 2012 Apr; 73(4):629-40. PubMed ID: 22007612
[TBL] [Abstract][Full Text] [Related]
10. CYP2C19 genotype plus platelet reactivity-guided antiplatelet therapy in acute coronary syndrome patients: a decision analysis.
Jiang M; You JH
Pharmacogenet Genomics; 2015 Dec; 25(12):609-17. PubMed ID: 26398625
[TBL] [Abstract][Full Text] [Related]
11. Both CYP2C19 and PON1 Q192R Genotypes Influence Platelet Response to Clopidogrel by Thrombelastography in Patients with Acute Coronary Syndrome.
Peng W; Shi X; Xu X; Lin Y
Cardiovasc Ther; 2019; 2019():3470145. PubMed ID: 31772608
[TBL] [Abstract][Full Text] [Related]
12. Influence of CYP2C19 polymorphisms on platelet reactivity and clinical outcomes in ischemic stroke patients treated with clopidogrel.
Qiu LN; Sun Y; Wang L; Han RF; Xia XS; Liu J; Li X
Eur J Pharmacol; 2015 Jan; 747():29-35. PubMed ID: 25489921
[TBL] [Abstract][Full Text] [Related]
13. Association of CYP2C19 genotype with periprocedural myocardial infarction after uneventful stent implantation in Chinese patients receiving clopidogrel pretreatment.
Wu H; Qian J; Sun A; Wang Q; Ge J
Circ J; 2012; 76(12):2773-8. PubMed ID: 22971905
[TBL] [Abstract][Full Text] [Related]
14. Effect of cytochrome P450 2C19 polymorphism on adverse cardiovascular events after drug-eluting stent implantation in a large Hakka population with acute coronary syndrome receiving clopidogrel in southern China.
Zhong Z; Hou J; Zhang Q; Li B; Li C; Liu Z; Yang M; Zhong W; He X; Wu H; Zhong M; Zhao P
Eur J Clin Pharmacol; 2018 Apr; 74(4):423-431. PubMed ID: 29243114
[TBL] [Abstract][Full Text] [Related]
15. Effect of CYP2C19*2 and *3 loss-of-function alleles on platelet reactivity and adverse clinical events in East Asian acute myocardial infarction survivors treated with clopidogrel and aspirin.
Jeong YH; Tantry US; Kim IS; Koh JS; Kwon TJ; Park Y; Hwang SJ; Bliden KP; Kwak CH; Hwang JY; Gurbel PA
Circ Cardiovasc Interv; 2011 Dec; 4(6):585-94. PubMed ID: 22045970
[TBL] [Abstract][Full Text] [Related]
16. Association of FMO3 rs1736557 polymorphism with clopidogrel response in Chinese patients with coronary artery disease.
Zhu KX; Song PY; He-Li ; Li MP; Du YX; Ma QL; Peng LM; Chen XP
Eur J Clin Pharmacol; 2021 Mar; 77(3):359-368. PubMed ID: 33089397
[TBL] [Abstract][Full Text] [Related]
17. High on-treatment platelet reactivity by ADP and increased risk of MACE in good clopidogrel metabolizers.
Marcucci R; Giusti B; Paniccia R; Gori AM; Saracini C; Valente S; Giglioli C; Parodi G; Antoniucci D; Gensini GF; Abbate R
Platelets; 2012; 23(8):586-93. PubMed ID: 22390861
[TBL] [Abstract][Full Text] [Related]
18. Impact of CYP2C19 Metabolizer Status on Patients With ACS Treated With Prasugrel Versus Clopidogrel.
Doll JA; Neely ML; Roe MT; Armstrong PW; White HD; Prabhakaran D; Winters KJ; Duvvuru S; Sundseth SS; Jakubowski JA; Gurbel PA; Bhatt DL; Ohman EM; Fox KAA;
J Am Coll Cardiol; 2016 Mar; 67(8):936-947. PubMed ID: 26916483
[TBL] [Abstract][Full Text] [Related]
19. Patients carrying CYP2C19 loss of function alleles have a reduced response to clopidogrel therapy and a greater risk of in-stent restenosis after endovascular treatment of lower extremity peripheral arterial disease.
Guo B; Tan Q; Guo D; Shi Z; Zhang C; Guo W
J Vasc Surg; 2014 Oct; 60(4):993-1001. PubMed ID: 24877854
[TBL] [Abstract][Full Text] [Related]
20. Effects of individualized antiplatelet therapy, based on CYP2C19 genotyping, on platelet function in patients underwent percutaneous coronary intervention.
Zhang M; Wang J; Zhang Y; Zhang P; Chao Y; Gao M; Hou Y
Perfusion; 2022 Jan; 37(1):78-85. PubMed ID: 33300437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]